Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Pituitary Neoplasms 7Neuroendocrine Tumors 6Carcinoid Tumor 5Acromegaly 5Prostatic Neoplasms 4Pancreatic Neoplasms 4Gastro-enteropancreatic neuroendocrine tumor 3Pituitary ACTH Hypersecretion 2Neoplasms 2Neoplasm Metastasis 2Nelson Syndrome 2Multiple Myeloma 2Liver Neoplasms 2Growth Disorders 2Gigantism 2Carcinoma, Intraductal, Noninfiltrating 2Carcinoma, Hepatocellular 2ACTH Syndrome, Ectopic 2Uveal Melanoma 1Thyroid Neoplasms 1Small Cell Lung Carcinoma 1Serotonin Syndrome 1Sarcoma, Synovial 1Prolactinoma 1Prolactin-Producing Pituitary Tumor 1Primary Inoperable Thymoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Peritoneal Neoplasms 1Pancreatic Fistula 1Neuroectodermal Tumors, Primitive 1

Interventions

Cabergoline 6Dopamine Agonists 2ropinirole 1pasireotide 1Tissue Banks 1Temozolomide 1Surgical Procedures, Operative 1Standard of Care 1Microarray Analysis 1Magnetic Resonance Spectroscopy 1Lapatinib 1Early Intervention, Educational 1Dexamethasone 1DNA Methylation 1Clomiphene 1Calcium Dobesilate 12,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prolactinoma × pasireotide × Clear all
NCT01620138 2016-08-22

Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas

Universidade Federal do Rio de Janeiro

Phase 2/3 Completed
21 enrolled 4 charts

Prolactinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡